<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19281096</article-id><article-id pub-id-type="pmc">2650616</article-id><article-id pub-id-type="publisher-id">copd-3-803</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Geographic differences in clinical characteristics and management of COPD: the EPOCA study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miravitlles</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="af1-copd-3-803">1</xref><xref ref-type="corresp" rid="c1-copd-3-803"/></contrib><contrib contrib-type="author"><name><surname>Murio</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="af2-copd-3-803">2</xref></contrib><contrib contrib-type="author"><name><surname>Tirado-Conde</surname><given-names>Gema</given-names></name><xref ref-type="aff" rid="af1-copd-3-803">1</xref></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Gur</given-names></name><xref ref-type="aff" rid="af3-copd-3-803">3</xref></contrib><contrib contrib-type="author"><name><surname>Muellerova</surname><given-names>Hana</given-names></name><xref ref-type="aff" rid="af4-copd-3-803">4</xref></contrib><contrib contrib-type="author"><name><surname>Soriano</surname><given-names>Joan B</given-names></name><xref ref-type="aff" rid="af5-copd-3-803">5</xref></contrib><contrib contrib-type="author"><name><surname>Ramirez-Venegas</surname><given-names>Alejandra</given-names></name><xref ref-type="aff" rid="af6-copd-3-803">6</xref></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Fanny WS</given-names></name><xref ref-type="aff" rid="af7-copd-3-803">7</xref></contrib><contrib contrib-type="author"><name><surname>Canelos-Estrella</surname><given-names>Byron</given-names></name><xref ref-type="aff" rid="af8-copd-3-803">8</xref></contrib><contrib contrib-type="author"><name><surname>Giugno</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="af9-copd-3-803">9</xref></contrib><contrib contrib-type="author"><name><surname>Bergna</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="af9-copd-3-803">9</xref></contrib><contrib contrib-type="author"><name><surname>Ch&#x000e9;rrez</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="af10-copd-3-803">10</xref></contrib><contrib contrib-type="author"><name><surname>Anzueto</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="af11-copd-3-803">11</xref></contrib></contrib-group><aff id="af1-copd-3-803"><label>1</label> Servei de Pneumologia, Institut Cl&#x000ed;nic del T&#x000f2;rax, Hospital Cl&#x000ed;nic, Barcelona, Spain</aff><aff id="af2-copd-3-803"><label>2</label> Secci&#x000f3; de Pneumologia, Hospital General de Catalunya, Barcelona, Spain</aff><aff id="af3-copd-3-803"><label>3</label> Servicio de Neumonolog&#x000ed;a, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela</aff><aff id="af4-copd-3-803"><label>4</label> GlaxoSmithKline, Greenford, UK and Research Triangle Park, USA</aff><aff id="af5-copd-3-803"><label>5</label> Programa de Epidemiolog&#x000ed;a e Investigaci&#x000f3;n Cl&#x000ed;nica, Fundaci&#x000f3;n Caubet-CIMERA Bunyola, Illes Balears, Spain</aff><aff id="af6-copd-3-803"><label>6</label> Departamento de Investigacion en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias, Ciudad de M&#x000e9;xico, M&#x000e9;xico</aff><aff id="af7-copd-3-803"><label>7</label> Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, New Territories, Peoples Republic of China</aff><aff id="af8-copd-3-803"><label>8</label> Hospital Metropolitano, Universidad Central del Ecuador y Pontificia Universidad Cat&#x000f3;lica del Ecuador, Quito, Ecuador</aff><aff id="af9-copd-3-803"><label>9</label> Hospital del T&#x000f3;rax Dr. Antonio Cetrangolo, Vicente L&#x000f3;pez, Buenos Aires, Argentina</aff><aff id="af10-copd-3-803"><label>10</label> RESPIRALAB-Hospital Kennedy, Guayaquil, Ecuador</aff><aff id="af11-copd-3-803"><label>11</label> Division of Pulmonary and Critical Care Medicine at the South Texas Veterans Health Care System Audie L Murphy Division and the University of Texas Health Science Center, San Antonio, TX USA</aff><author-notes><corresp id="c1-copd-3-803">Correspondence: Marc Miravitlles, Pneumology Department, Institut Cl&#x000ed;nic del T&#x000f2;rax, Hosp&#x000ec;tal Clin&#x000ed;c, Villarroel 170, Barcelona 08036, Spain, Tel/Fax +34 93 227 5549, Email<email>marcm@clinic.ub.es</email></corresp></author-notes><!--Dove Press titles changed from ppub to collections in 2009.								Fake epub written to satisfy Base Date Type=epub--><pub-date pub-type="ppub"><month>12</month><year>2008</year></pub-date><pub-date pub-type="epub"><month>12</month><year>2008</year></pub-date><volume>3</volume><issue>4</issue><fpage>803</fpage><lpage>814</lpage><copyright-statement>&#x000a9; 2008 Dove Medical Press Limited. All rights reserved</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Aims</title><p>Data on differences in clinical characteristics and management of COPD in different countries and settings are limited. We aimed to characterize the profile of patients with COPD in a number of countries and their treatment in order to evaluate adherence to recommendations of international guidelines.</p></sec><sec sec-type="methods"><title>Method</title><p>This was an observational, international, cross-sectional study on patients with physician-diagnosed COPD. Demographic and clinical characteristics, risk factors, and treatment were collected by their physician via an internet web-based questionnaire developed for the study.</p></sec><sec><title>Results</title><p>A total of 77 investigators from 17 countries provided data on 833 patients. The countries with the highest number of patients included were: Argentina (128), Ecuador (134), Spain (162), and Hong Kong (153). Overall, 79.3% were men and 81% former smokers, with a mean FEV<sub>1</sub> = 42.7%, ranging from 34.3% in Hong Kong to 58.8% in Ecuador. Patients reported a mean of 1.6 exacerbations the previous year, with this frequency being significantly and negatively correlated with FEV<sub>1</sub>(%) (r = &#x02212;0.256; p &#x0003c; 0.0001). Treatment with short-acting bronchodilators and theophyllines was more frequent in Ecuador and Hong Kong compared with Spain and Argentina, and in patients belonging to lower socioeconomic levels (p &#x0003c; 0.0001 for all comparisons). Inadequacy of treatment with inhaled corticosteroids and theophyllines was high, with significant differences among countries.</p></sec><sec><title>Conclusions</title><p>Differences in the clinical characteristics and management of COPD were significant across countries. Adherence to international guidelines appears to be low. Efforts should be made to disseminate and adapt guidelines to the socioeconomic reality of different settings.</p></sec></abstract><kwd-group><kwd>COPD</kwd><kwd>epidemiology</kwd><kwd>EPOCA</kwd><kwd>socioeconomics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is an important public healthcare problem throughout the world. Despite anti-smoking campaigns, its prevalence and mortality rate continue rising every year (<xref ref-type="bibr" rid="b18-copd-3-803">Jemal et al 2005</xref>). By 2020 it is estimated that COPD will be the fifth cause of disability and the third cause of death (<xref ref-type="bibr" rid="b28-copd-3-803">Pauwels et al 2001</xref>).</p><p>A previous epidemiologic study demonstrated the prevalence of COPD in the general Spanish population between 40 and 70 years of age to be of 9.1% (<xref ref-type="bibr" rid="b33-copd-3-803">Sobradillo et al 2000</xref>). However, more importantly, it was observed that 78% of the patients identified with COPD had not been previously diagnosed with the disease, and 60% of these patients were not being treated according to the current guidelines (<xref ref-type="bibr" rid="b33-copd-3-803">Sobradillo et al 2000</xref>; <xref ref-type="bibr" rid="b24-copd-3-803">Miravitlles et al 2005</xref>). Worldwide, the prevalence of COPD in the general population is estimated to be 1% across all ages, rising steeply to 8% to 10% or higher among those aged 40 years and with nearly 80% of COPD cases remaining undiagnosed (<xref ref-type="bibr" rid="b7-copd-3-803">Chapman et al 2006</xref>; <xref ref-type="bibr" rid="b13-copd-3-803">Halbert et al 2006</xref>). Most of the information on the characteristics of patients with COPD and the patterns of treatment derive from a series of studies conducted in North America and Europe (<xref ref-type="bibr" rid="b17-copd-3-803">Jackevicius et al 1997</xref>; <xref ref-type="bibr" rid="b26-copd-3-803">Miravitlles et al 1999</xref>; <xref ref-type="bibr" rid="b31-copd-3-803">Roche et al 2001</xref>; <xref ref-type="bibr" rid="b9-copd-3-803">De Miguel et al 2003</xref>; <xref ref-type="bibr" rid="b11-copd-3-803">Esteban et al 2006</xref>). Few studies have provided data from countries from other parts of the world, although the prevalence of COPD is also high in Latin America (<xref ref-type="bibr" rid="b20-copd-3-803">Menezes et al 2005</xref>), Korea (<xref ref-type="bibr" rid="b19-copd-3-803">Kim et al 2005</xref>), Taiwan (<xref ref-type="bibr" rid="b36-copd-3-803">Wang et al 2007</xref>), China (<xref ref-type="bibr" rid="b37-copd-3-803">Zhong et al 2007</xref>), and Japan (<xref ref-type="bibr" rid="b12-copd-3-803">Fukuchi et al 2004</xref>). Exposure to respiratory risk factors also differ between geographic areas (<xref ref-type="bibr" rid="b20-copd-3-803">Menezes et al 2005</xref>; <xref ref-type="bibr" rid="b37-copd-3-803">Zhong et al 2007</xref>) and these, together with genetic determinants and patterns of smoking, may be the reason for the different characteristics and severity of COPD across countries (<xref ref-type="bibr" rid="b3-copd-3-803">Buist et al 2007</xref>).</p><p>In recent years, epidemiological studies have demonstrated a high and increasing burden of COPD worldwide (<xref ref-type="bibr" rid="b7-copd-3-803">Chapman et al 2006</xref>; <xref ref-type="bibr" rid="b13-copd-3-803">Halbert et al 2006</xref>). Moreover, the adherence of treatment to currently accepted guidelines is poor in many countries (<xref ref-type="bibr" rid="b26-copd-3-803">Miravitlles et al 1999</xref>; <xref ref-type="bibr" rid="b31-copd-3-803">Roche et al 2001</xref>; <xref ref-type="bibr" rid="b30-copd-3-803">Rennard et al 2002</xref>; <xref ref-type="bibr" rid="b9-copd-3-803">De Miguel et al 2003</xref>).</p><p>The EPOCA (Enfermedad Pulmonar Obstructiva Cr&#x000f3;nica en Acci&#x000f3;n) project is an international web-based survey of doctors and their COPD patients, aimed at comparing the clinical and demographic characteristics, risk factors, and treatment of patients with COPD in different areas of the world using a common protocol through the internet.</p></sec><sec sec-type="methods"><title>Method</title><sec><title>Design</title><p>This was a prospective, international, cross-sectional, observational survey of outpatients diagnosed with COPD. The full data collection period included one year, from December 2005 to December 2006. Data were collected through a web-enabled database developed in two languages, English and Spanish. Physicians interested in COPD were recruited using email addresses retrieved from their publications in the field and were invited to participate by email. We aimed to have a representation of different geographic areas by contacting leading investigators who could invite colleagues in their area to join the study. Each investigator was provided with a username and a password to access an online study questionnaire. They were allowed to visualize and modify data of only their own patients. None of the investigators received any payment for participating in the study. Since the main study objectives were descriptive and group comparisons analyses were not planned, we did not make a pre-specified calculation of sample size.</p></sec><sec><title>Ethics</title><p>The design of the EPOCA website fulfilled all standards of data protection. Since the server was located in Barcelona (Spain), the database was declared to the Spanish authorities. No data were collected that could help to identify any single patient in the database. The study was approved by a central ethics committee of the Hospital Cl&#x000ed;nic of Barcelona, Spain. Informed consent forms were available in the website for downloading in English and Spanish. Written or oral informed consent was obtained for the patients to be included in the study, according to local legislation for observational, non-interventional studies in each country.</p></sec><sec><title>Study population</title><p>This was an international, multicenter study in real life practice with a large number of investigators in different settings; therefore we wanted to minimize the risk of misclassification or misdiagnosis as much as possible by not including life-long never smokers. The inclusion criteria were: a) aged older than 40 years; b) smokers or former smokers of at least 10 pack-years; and c) had forced spirometry with a post-bronchodilator FEV<sub>1</sub>/FVC &#x0003c; 70%.</p><p>Exclusion criteria were diagnoses of: a) bronchial asthma; b) severe bronchiectasis; c) active tuberculosis and any other chronic infectious disease.</p></sec><sec><title>Study variables</title><p>The data collected included age, sex, race, socioeconomic and educational level, and risk factors and clinical characteristics of COPD. Socioeconomic level was categorized by the investigators into high, intermediate, or low according to the gross national income and related to the values for their country. Clinical characteristics of COPD included spirometric results as well as the number of previous exacerbations, emergency visits and hospitalizations due to exacerbations in the previous 12 months and healthcare utilization. Owing to the characteristics of the study, standardization of the spirometric measurements was not possible and each investigator was requested to observe American Thoracic Society criteria for standardization of spirometric procedures (<xref ref-type="bibr" rid="b2-copd-3-803">American Thoracic Society 1995</xref>). Post-bronchodilator values were used for the analysis whenever available.</p><p>The treatment patterns identified included drug treatments, vaccination, rehabilitation, and long-term oxygen therapy. Adherence of prescribed treatments to the current guidelines was assessed for inhaled corticosteroids (ICS) and theophyllines. According to the GOLD guidelines existent at the time of data collection (<xref ref-type="bibr" rid="b28-copd-3-803">Pauwels et al 2001</xref>), ICS were indicated in patients with FEV<sub>1</sub> less than 50% predicted and with one or more exacerbations and/or visits to emergency rooms and/or admissions. Theophyllines were indicated as a second-line treatment after long-acting beta2-agonists (LABAs) and tiotropium in severe patients. To be restrictive in the indication for severe patients, we decided to use a cut off level of FEV<sub>1</sub> less than 30% predicted in patients already treated with LABAs and/or tiotropium. For both groups of drugs the percentages of not indicated drugs among the prescribed and the percentage of not prescribed over the indicated was calculated.</p></sec><sec><title>Statistical analysis</title><p>Main variables are presented as percentages. Countries with the largest participation were identified and clinical and treatment characteristics of COPD among the patients recruited in these countries were compared. We used a parametric test (Student&#x02019;s t-test) for variables with a normal distribution and non-parametric test (Mann-Whitney test) for non normally distributed variables. Percentages were compared by means of the chi-squared test. A p value less than 0.05 was considered significant.</p><p>Factors potentially associated with exacerbations, prescription of ICS, combination therapy of LABA + ICS, and tiotropium were studied using stepwise logistic regression analysis with the statistical package SAS version 8.02.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient demographic characteristics</title><p>A total of 77 investigators from 17 countries included data from at least one patient in the database. The total number of patients included was 833, representing a mean of 10.8 patients per investigator. The countries/areas with the highest number of recruited patients were: Spain (n = 162), Hong-Kong (n = 153), Ecuador (n = 134), and Argentina (n = 128); these were further analyzed.</p><p>Patient demographic characteristics are summarized in <xref ref-type="table" rid="t1-copd-3-803">Table 1</xref>. Mean age was 69.5 (SD = 10.2) years, 78.2% of participants were men, and only 19.4% were active smokers. Mean tobacco consumption for both smokers and ex-smokers was 47.7 pack-years (SD = 34 pack-years). Most of the patients had attended, either finished (24.5%) or unfinished (29.3%), only primary school, and only 8.3% had a university degree. Most individuals were retired (59.4%) and only 23.2% were active, either part- or full-time, workers. According to the investigator&#x02019;s perception, 38.2% of patients belonged to a lower socioeconomic class, 54.4% to a middle class, and 7.2% were ranked as upper class.</p><p>There were significant differences in most of the demographic characteristics across countries. For instance, patients in Hong Kong showed the lowest body mass index (21.7), the oldest mean age (74.9 years), and the highest proportion of males (90.8%). Mean tobacco consumption was highest in Argentina (58.1 pack-years) and highest exposure to biomass smoke was in Hong Kong and Ecuador (43% and 32.3%, respectively) (p &#x0003c; 0.0001 for all comparisons) (<xref ref-type="table" rid="t1-copd-3-803">Table 1</xref>).</p></sec><sec><title>Characteristics of COPD</title><p>Dyspnea on exertion was the most frequent symptom (97.8%), with 54.8% of patients presenting dyspnea MRC degree III or IV. Mean FEV<sub>1</sub>% predicted was 42.7% (SD = 17.8%). The patients presented a mean of 1.6 (SD = 2) exacerbations, 1.5 (SD = 2.5) visits to the general practitioner and 2.4 (SD = 2.6) visits to the chest specialist in the previous 12 months (<xref ref-type="table" rid="t2-copd-3-803">Table 2</xref>). The frequency of exacerbations was significantly, albeit weakly, correlated with COPD severity, as measured by FEV<sub>1</sub>(%), giving a correlation factor (r) of &#x02212;0.256 (p &#x0003c; 0.0001) (<xref ref-type="fig" rid="f1-copd-3-803">Figure 1</xref>).</p><p>Analysis of differences among countries showed several highly significant items. Chronic respiratory symptoms, cough and sputum, were most frequent in Ecuador (87.4% and 92.1%, respectively). Mean FEV<sub>1</sub> ranged from 34.3% in Hong Kong to 58.8% in Ecuador. Use of healthcare resources also differed by country. The mean number of admissions ranged from 1 per patient per year in Hong Kong to 0.4 in Ecuador and the mean number of visits to a chest specialist from 1.8 in Spain and Hong Kong to 4.6 in Argentina (p &#x0003c; 0.0001 for all comparisons) (<xref ref-type="table" rid="t2-copd-3-803">Table 2</xref>).</p></sec><sec><title>Treatment of COPD</title><p>The most frequently prescribed treatment for COPD was short-acting beta-agonists (SABA) (74.8%) followed by ipratropium (48.3%), with large differences between countries. SABAs were prescribed in a range from 90.1% in Hong Kong to 21.1% in Spain. Tiotropium was used by 73.9% of patients in Spain and only 1.9% in Hong Kong. Combined treatment of LABA and ICS was used by 45.9% of patients, ranging from 12.5% in Hong Kong to 72.8% in Argentina (all differences were statistically significant, <xref ref-type="table" rid="t3-copd-3-803">Table 3</xref>). Oral treatment was prescribed less frequently; theophyllines were used by 25.3% of the sample, with maximum frequency in Hong Kong (46.6%). Only 15.6% of patients were following a rehabilitation program, mostly in Argentina (30.5%). Interestingly, 58.6% had received the anti-influenza vaccine the previous year, with the lowest percentage in Ecuador (22.6%). Antipneumococcal vaccine was administered to 32.5%, with almost no use in Hong Kong (0.7%) and a maximum in Argentina (64.4%).</p><p>When compared with recommendations based on international guidelines (<xref ref-type="bibr" rid="b28-copd-3-803">Pauwels et al 2001</xref>), we observed non-compliance with these recommendations in a significant number of patients. Specifically, 306 patients fulfilled indications for chronic treatment with ICS and 527 were regularly treated with ICS. Up to 27.8% of those with an indication for ICS treatment were not receiving them, and, according to the guidelines, 41.9% of patients treated with ICS did not fulfil the indications for treatment. This inadequacy varied significantly among countries (<xref ref-type="table" rid="t4-copd-3-803">Table 4</xref>). Theophyllines were administered to 222 patients while 123 had indications for treatment with this drug. However, up to 79.6% of the patients with indication for theophyllines were not receiving them, and, according to the guidelines, 26.6% of patients treated with theophyllines had no indication. Differences were, again, large and significant among countries (<xref ref-type="table" rid="t4-copd-3-803">Table 4</xref>).</p></sec><sec><title>Differences according to estimated social class</title><p>Patients of a lower socioeconomic class were older and had a more severe impairment of FEV<sub>1</sub>(%) than patients belonging to an upper class. They were also more exposed to biomass smoke (36.1% vs 13.5% and 18.6% for low, middle, and high class, respectively, p &#x0003c; 0.0001). Lower class patients tended to require more visits to emergency rooms and admissions for exacerbations (p = 0.058 and p = 0.083, respectively) (<xref ref-type="table" rid="t5-copd-3-803">Table 5</xref>).</p><p>Treatments differed according to the class; SABAs, LABAs, ipratropium, and theophyllines were more frequently prescribed to lower class patients and tiotropium and combination therapy LABA + ICS were less frequently used by lower class patients (all comparisons p &#x0003c; 0.0001). Rehabilitation was more frequent in upper class patients (31.5% compared with 15.7% and 13.4% in middle and lower classes, respectively; p = 0.0036) (<xref ref-type="table" rid="t5-copd-3-803">Table 5</xref>).</p></sec><sec><title>Analysis of factors associated with exacerbations and prescribed drugs</title><p>Stepwise regression analysis identified the variables significantly associated with the frequency of exacerbations categorized as 0&#x02013;1 versus more than 1. Older age, increasing baseline dyspnea, and use of ICS were associated with an increased frequency of exacerbations in the model (<xref ref-type="table" rid="t6-copd-3-803">Table 6a</xref>).</p><p>In terms of pharmacologic treatment, use of ICS was significantly associated with more impaired lung function and the presence of expectoration. Patients belonging to the upper class, active smokers, and Spanish were less likely to use ICS alone compared with lower classes, former smokers, and patients from Argentina, Ecuador, and Hong Kong (<xref ref-type="table" rid="t6-copd-3-803">Table 6b</xref>). In contrast, Spanish patients were more likely to use combination therapy with LABA + ICS than patients from Ecuador or Hong Kong, and patients with secondary schooling, former smokers, or with chronic cough were more likely to be prescribed the combination of LABA + ICS (<xref ref-type="table" rid="t6-copd-3-803">Table 6c</xref>). Finally, use of tiotropium was associated only with geographic variables, with patients from Argentina, Ecuador, or Hong Kong being less likely to be treated with this drug than patients from Spain (<xref ref-type="table" rid="t6-copd-3-803">Table 6</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study shows that there are significant and relevant differences in the clinical characteristics, exposure to risk factors, and patterns of management of patients with COPD in different areas of the world. Differences in genetic background may account for part of the variations shown by the results. However, different toxic exposures, differences in socioeconomic and living conditions, and differences in education levels also exist and may be responsible, at least in part, for the variations observed in the manifestations of COPD. Epidemiological studies have demonstrated important variations in the prevalence of smoking in young adults across countries and, as a consequence, a large variation in the prevalence of chronic bronchitis (<xref ref-type="bibr" rid="b6-copd-3-803">Cerveri et al 2001</xref>) and COPD (<xref ref-type="bibr" rid="b8-copd-3-803">De Marco et al 2004</xref>). However, the same authors indicated that only 30% of the geographical variability in prevalence could be explained by differences in smoking habits, suggesting other factors such as environmental exposure or genetic background as contributors to this variability (<xref ref-type="bibr" rid="b6-copd-3-803">Cerveri et al 2001</xref>).</p><p>The clinical characteristics of patients with COPD have been carefully studied in clinical trials (<xref ref-type="bibr" rid="b5-copd-3-803">Calverley et al 2007</xref>). However, due to the restrictive inclusion and exclusion criteria, these characteristics differ significantly from those of COPD patients in general practice. In fact, a Swedish study demonstrated that less than 20% of patients with COPD attended by general practitioners share characteristics with patients included in clinical trials (<xref ref-type="bibr" rid="b16-copd-3-803">Herland et al 2005</xref>). Therefore, surveys conducted in real clinical practice in different areas of the world with broad inclusion criteria are required to identify the characteristics, risk factors, and patterns of management of COPD in real life.</p><p>Data from international surveys of patients with COPD in real life are scarce. Two previous surveys identified patients through random telephone calls (<xref ref-type="bibr" rid="b30-copd-3-803">Rennard et al 2002</xref>; <xref ref-type="bibr" rid="b21-copd-3-803">Miravitlles et al 2007</xref>). The Confronting Survey performed in 6 European countries, the US, and Canada demonstrated the significant impact of COPD on daily life activities and how patients underestimate disease severity. Furthermore, only 45% of patients had undergone spirometry for diagnosis (<xref ref-type="bibr" rid="b30-copd-3-803">Rennard et al 2002</xref>). Similarly, in a large survey conducted in Spain in 6,758 adults, the prevalence of chronic respiratory symptoms was 36%, but only 56% of the individuals with symptoms consulted a physician and of these, only 42% underwent spirometry (<xref ref-type="bibr" rid="b22-copd-3-803">Miravitlles et al 2006</xref>). The Perceive Study, conducted in 5 European countries and the US demonstrated the burden associated with the exacerbations of COPD and the impact of the exacerbations on daily life activities (<xref ref-type="bibr" rid="b21-copd-3-803">Miravitlles et al 2007a</xref>). In contrast with the current study, no confirmation of the diagnosis or severity of COPD was possible because of the lack of spirometry in the aforementioned surveys. Moreover, they collected information only on patients from Europe and North America and no data from Asia-Pacific or Latin America were available. In our study only patients with confirmed COPD by spirometry were included and most of the patients had post-bronchodilator values. However, a few patients had only one value registered for spirometry. Most were severe patients who needed to take their bronchodilators to relieve their severe dyspnea before attending the clinics and perform spirometry; therefore, their values can be considered post-bronchodilator values. Additionally, although we recognize the importance of COPD in never smokers, we recruited only patients who were either smokers or ex-smokers to avoid misclassification of patients with other respiratory diseases such as asthma.</p><p>Recent well-conducted epidemiological studies have provided information on the burden of the disease in those areas. The PLATINO project observed a prevalence of COPD (GOLD II to IV) in Latin America ranging from 2.9% in Mexico City to 7.1% in Montevideo, again highlighting the importance of geographical variation (<xref ref-type="bibr" rid="b20-copd-3-803">Menezes et al 2005</xref>). Using the same protocol, the BOLD initiative, performed in 12 sites around the world, demonstrated a significant variation in the prevalence of COPD (GOLD II to IV), ranging from 8.5% in males in Reykjavik to 22.2% in Cape Town and from 3.7% in women in Hanover to 16.7% in Cape Town. Interestingly, significant heterogeneity was observed between sites, especially in women (<xref ref-type="bibr" rid="b3-copd-3-803">Buist et al 2007</xref>). These differences can be observed among different areas of the same country, as was demonstrated in a Spanish study in 7 different cities, in which the prevalence of COPD ranged from 4.9% to 18% (<xref ref-type="bibr" rid="b33-copd-3-803">Sobradillo et al 2000</xref>). Not only prevalence but also severity of impairment in functional status and perceived health may vary in different racial groups within the same country, as demonstrated in different population groups in the US (<xref ref-type="bibr" rid="b1-copd-3-803">Adams et al 2006</xref>). At least part of these differences can be caused by exposure to other risk factors, such as biomass smoke exposure (<xref ref-type="bibr" rid="b29-copd-3-803">Ramirez-Venegas et al 2006</xref>) or environmental exposure (<xref ref-type="bibr" rid="b27-copd-3-803">Montn&#x000e9;mery et al 2001</xref>). A significant exposure to biomass fuel was declared by 42% of the COPD patients in Hong Kong and in 32% in Ecuador, compared with only 8% in Spain or 15% in Argentina. Other possibilities are the different perception of symptoms, which have demonstrated to be related to cultural factors in some racial groups (<xref ref-type="bibr" rid="b14-copd-3-803">Han et al 2005</xref>).</p><p>We observed significant differences in the characteristics and management of the disease according to the socioeconomic status of the patients. It is important to point out the existing limitations for adequate classification of socioeconomic status among different countries. However, the results obtained are consistent with other published national series (<xref ref-type="bibr" rid="b27-copd-3-803">Montn&#x000e9;mery et al 2001</xref>; <xref ref-type="bibr" rid="b10-copd-3-803">Ellison-Loschmann et al 2007</xref>; Hegwald and Crapo et al 2007). The current results demonstrate a higher exposure to biomass fuel in patients with lower socioeconomic status and better lung function in upper classes. Treatment also showed some differences, with a higher use of old, cheaper, SABAs and theophyllines and a lower use of tiotropium and combination therapy with LABA + ICS in patients of lower class and education. This variation in the use of drugs may largely be due to the economic level of the patients since national health coverage was poor in the countries showing the highest differences. These results concur with other epidemiological surveys which demonstrated a significant negative correlation between lung function and socioeconomic status (<xref ref-type="bibr" rid="b15-copd-3-803">Hegewald and Crapo 2007</xref>). However, there is a lack of evidence of the long-term impact of inadequate or insufficient treatment of COPD in patients of lower socioeconomic status, as observed in our study.</p><p>Exacerbations are a frequent event in the natural history of COPD. Our patient population had had a mean of 1.6 episodes the previous year and the frequency of exacerbations was significantly associated with an older age and a more severe baseline dyspnea. There was a weak but significant correlation between a more impaired FEV<sub>1</sub>(%) and more frequent exacerbations (r = &#x02212;0.256; p &#x0003c; 0.0001). The relationship between impaired lung function and more frequent exacerbations has been observed in clinical trials (<xref ref-type="bibr" rid="b4-copd-3-803">Burge and Wedzicha 2003</xref>) and observational studies (<xref ref-type="bibr" rid="b26-copd-3-803">Miravitlles et al 1999</xref>), but it has also been demonstrated in this study in heterogeneous populations from different countries, which together reinforces the relationship between the natural history of the disease and the frequency of exacerbations.</p><p>Most patients received treatment for COPD and this treatment differed widely among countries, suggesting that implementation of international guidelines is not uniform around the world. SABAs are widely used, but more new and expensive drugs such as tiotropium and combination therapy with LABA + ICS are more frequently prescribed in countries with a higher economic level and in patients of higher socioeconomic classes. In fact, country was the only variable significantly associated with prescription of the three drugs analyzed in multivariate models. The lack of adherence to treatment guidelines for COPD has been extensively demonstrated in previous studies (<xref ref-type="bibr" rid="b17-copd-3-803">Jackevicius et al 1997</xref>; <xref ref-type="bibr" rid="b26-copd-3-803">Miravitlles et al 1999</xref>; <xref ref-type="bibr" rid="b31-copd-3-803">Roche et al 2001</xref>; <xref ref-type="bibr" rid="b30-copd-3-803">Rennard et al 2002</xref>; <xref ref-type="bibr" rid="b9-copd-3-803">De Miguel et al 2003</xref>; <xref ref-type="bibr" rid="b11-copd-3-803">Esteban et al 2006</xref>; <xref ref-type="bibr" rid="b23-copd-3-803">Miravitlles et al 2007b</xref>). Our results highlight this problem and identify some of the aspects related to the prescription of different drugs. Another interesting observation is the analysis of prescription of theophyllines and ICS. Evolutionary studies have demonstrated that theophyllines have been replaced by the use of ICS in patients with COPD over time (<xref ref-type="bibr" rid="b34-copd-3-803">Van Andel et al 1999</xref>). However, the use of theophyllines is still very frequent in countries such as Hong Kong and Ecuador, probably for economic reasons. According to the guidelines at the time of data collection, there was a lack of adjustment in the use of these two drugs. According to the guidelines, 41.9% of the prescriptions of ICS were not prescribed correctly and, conversely, in 27.8% of the cases in which they were indicated, the ICS were not prescribed. Similarly, a large survey on 11,973 patients with COPD in Spain showed that 69% of patients with mild COPD were receiving ICS regularly (<xref ref-type="bibr" rid="b35-copd-3-803">Viejo-Ba&#x000f1;uelos et al 2006</xref>). A recent study has shown that some patients with COPD receiving ICS had clinical characteristics similar to asthma (<xref ref-type="bibr" rid="b23-copd-3-803">Miravitlles et al 2007b</xref>) which could justify its use even if FEV<sub>1</sub> is above 50% predicted (<xref ref-type="bibr" rid="b32-copd-3-803">Siva et al 2007</xref>). Most patients with an indication of theophyllines were not receiving them, perhaps because of the risk of side effects, whereas 26.6% of patients treated with theophyllines should have received other more appropriate drugs.</p><p>The EPOCA study was an attempt to characterize COPD patients and patterns of management in different countries by using the same protocol and with a simple and fast data collection through a web-enabled database on the internet. This is one of the few observational studies performed in COPD patients using this new technology (<xref ref-type="bibr" rid="b25-copd-3-803">Miravitlles et al 2002</xref>). Despite its relatively small sample size, it has allowed the identification of significant differences in the clinical characteristics and management of COPD across countries. The results do not aim to be fully representative of the populations of COPD patients in each of the countries participating. The selection of investigators was not random or weighted according to the population of the countries. To perform such a full-scale representative survey would be a tremendous task, clearly beyond the scope and the possibilities of our study. However, keeping this limitation in mind, our results demonstrate, at an international level, the large variability of characteristics of COPD patients and their management. The results obtained have shown that the characteristics of patients with COPD vary in different countries and patterns of management differ according to socioeconomic factors. A significant number of patients were not receiving treatment according to guidelines, which may result in suboptimal effects of therapy. More efforts are required to disseminate and implement international guidelines and attempt to adapt these guidelines to the socioeconomic reality of each setting. The national scientific societies may play an important role in disseminating the guidelines through national key opinion leaders, local publications translated into their own languages and local scientific meetings.</p></sec></body><back><ack><title>Acknowledgments</title><p>The EPOCA study was funded by an educational grant from GlaxoSmithKline R&#x00026;D.</p></ack><fn-group><fn><p><bold>Disclosures</bold></p><p>HM is an employee of GlaxoSmithKline, the company sponsoring this study. The other authors have no conflicts of interest to declare in relation to this manuscript.</p></fn><fn><p><bold>Author contribution</bold></p><p>Marc Miravitlles, study design, analysis and interpretation of data, and writing of the manuscript. Antonio Anzueto, study design, analysis and interpretation of data, and critical review of the manuscript. Cristina Murio, analysis and interpretation of data, monitoring of the study, and critical review of the manuscript. Gema Tirado-Conde, Gur Levy, Alejandra Ramirez-Venegas, Fanny Ko, Byron CanelosEstrella, Eduardo Giugno, Miguel Bergna, and Ivan Ch&#x000e9;rrez, data collection, critical review of the manuscript. Hana Muellerova securing funding for the study, study design, and critical review of the manuscript. Joan B. Soriano, study design, analysis and interpretation of data and critical review of the manuscript.</p></fn></fn-group><app-group><app id="app1-copd-3-803"><title>Appendix 1</title><sec><title>Organization of the EPOCA study</title><p>Scientific Committee</p><p>Marc Miravitlles (Barcelona, Spain), Antonio Anzueto (San Antonio, TX, United States), Gur Levy (Caracas, Venezuela), Cristina Murio (Barcelona, Spain), Joan B Soriano (Bu&#x000f1;ola, Spain), Hana Muellerova (Greenford, United Kingdom).</p><p>The following investigators participated in the study: <bold>Argentina:</bold> Pablo Luis Acrogliano; Miguel Bergna; Carmela Echag&#x000fa;e; Mariano Fern&#x000e1;ndez Acquier; Juan C. Figueroa Casas; Gabriel Garc&#x000ed;a; Eduardo Giugno; Georgina Gramblicka; Julio Alberto Herscovich; N&#x000e9;stor Sergioka Hanovsky; Jos&#x000e9; Mar&#x000ed;a Leston; Eduardo H&#x000e9;ctor Marzorati; Mar&#x000ed;a Cristina Ortiz; Salvador Antonio Pace; Fernando Saldarini; Jos&#x000e9; Luis Sarquis; Mirta Beatriz Scarinci; Marcela Soria; Carlos Fabi&#x000e1;n Victorio; Nora Miriam Zanollo. <bold>Brazil:</bold> Jos&#x000e9; R. Jardim; F&#x000e1;tima Saia Gonzaga; Carlos Eduardo Do Valle Ribeiro. <bold>Chile:</bold> Paulina Barr&#x000ed;a P&#x000e9;rez; Patricio Jim&#x000e9;nez; Carmen Lisboa; <bold>Cuba:</bold> Yadira Dobarganes Sans&#x000f3;n; Alfredo Jan&#x000e9; Lara. <bold>Ecuador:</bold> Betty Mar&#x000ed;a Aguilar De Baja&#x000f1;a; Oswaldo Bastidas Jervez; Carlos Andr&#x000e9;s Beltr&#x000e1;n Bastidas; Byron Canelos Estrella; Iv&#x000e1;n Cherrez Ojeda; Jos&#x000e9; Mat&#x000ed;as Desiderio Rodrigo; Melida Herlinda Jacome Escobar; Carlos Patricio Rosero Herrera. <bold>Spain:</bold> Cristian De La Roza Fern&#x000e1;ndez; Mikel Egurrola Izquierdo; Cristina Estirado Vera; Xavier Flor Escriche; Beatriz Lara; Montserrat Mas Pujol; Jos&#x000e9; Antonio Quintano Jimenez; Joan Sala Barbany; Alejandro Sanchez Acosta; Juan Jos&#x000e9; Soler Catalu&#x000f1;a; Xavier Soler Tomas; &#x000c1;ngel Tirado Conde; Gema Tirado Conde; Sara Vil&#x000e0; Valls; <bold>Greece:</bold> Epaminondas Kosmas. <bold>Honduras:</bold> Carlos Aguilar. <bold>Hong-Kong:</bold> Fanny WS Ko. <bold>Italy:</bold> Francesco Blasi; Luca Richeldi. <bold>Mexico:</bold> Javier D&#x000ed;az-Casta&#x000f1;on; Carlos Adrian Jim&#x000e9;nez Gonz&#x000e1;lez; Alejandra Ram&#x000ed;rez Venegas; Ra&#x000fa;l Sansores. <bold>Peru:</bold> Alberto Matsuno Fuchigami. <bold>Poland:</bold> Nowinski Adam; Justyna Czerniawska; Anna Czyzak; Jacek Kolakowski; Damian Korzybski. <bold>Russia:</bold> Ekaterina Bukreeva; Sofya Nesterovich; Mar&#x000ed;a Sanzharovskaja. <bold>South Africa:</bold> Gillian Ainslie. <bold>Uruguay:</bold> Mar&#x000ed;a Turquesa Anido Donceli; Mar&#x000ed;a Victoria L&#x000f3;pez Varela; Monica Mamchur Galvez; Sandra Pe&#x000f1;a Miraldo. <bold>Venezuela:</bold> Federico Arteta; Gur Levy.</p><p>Statistical analysis: Montse P&#x000e9;rez, Barcelona, Spain.</p></sec></app></app-group><ref-list><title>References</title><ref id="b1-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>SG</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Pugh</surname><given-names>JA</given-names></name><etal/></person-group><year>2006</year><article-title>Mexican American elders have similar severities of COPD despite less tobacco exposure thank European American elders</article-title><source>Respir Med</source><volume>100</volume><fpage>1966</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16626949</pub-id></citation></ref><ref id="b2-copd-3-803"><citation citation-type="journal"><collab>American Thoracic Society</collab><year>1995</year><article-title>Standardization of spirometry, 1994 update</article-title><source>Am J Respir Crit Care Med</source><volume>152</volume><fpage>1107</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7663792</pub-id></citation></ref><ref id="b3-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>McBurnie</surname><given-names>MA</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><etal/></person-group><year>2007</year><article-title>International variation in the prevalence of COPD (The BOLD study): a population-based prevalence study</article-title><source>Lancet</source><volume>370</volume><fpage>741</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17765523</pub-id></citation></ref><ref id="b4-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>S</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><year>2003</year><article-title>COPD exacerbations: definitions and classification</article-title><source>Eur Respir J</source><volume>21</volume><fpage>46</fpage><lpage>53</lpage></citation></ref><ref id="b5-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><etal/></person-group><year>2007</year><article-title>Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><volume>356</volume><fpage>775</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">17314337</pub-id></citation></ref><ref id="b6-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerveri</surname><given-names>I</given-names></name><name><surname>Accordini</surname><given-names>S</given-names></name><name><surname>Verlato</surname><given-names>G</given-names></name><etal/></person-group><year>2001</year><article-title>Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults</article-title><source>Eur Respir J</source><volume>18</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11510810</pub-id></citation></ref><ref id="b7-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Soriano</surname><given-names>JB</given-names></name><etal/></person-group><year>2006</year><article-title>Epidemiology and costs of chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><volume>27</volume><fpage>188</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">16387952</pub-id></citation></ref><ref id="b8-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>R</given-names></name><name><surname>Accordini</surname><given-names>S</given-names></name><name><surname>Cerveri</surname><given-names>I</given-names></name><etal/></person-group><year>2004</year><article-title>An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages</article-title><source>Thorax</source><volume>59</volume><fpage>120</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14760151</pub-id></citation></ref><ref id="b9-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Miguel</surname><given-names>J</given-names></name><name><surname>Izquierdo Alonso</surname><given-names>JL</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>Gonz&#x000e1;lez-Moro</given-names></name><etal/></person-group><year>2003</year><article-title>Tratamiento farmacol&#x000f3;gico de la EPOC en dos niveles asistenciales. Grado de adecuaci&#x000f3;n a las normativas recomendadas</article-title><source>Arch Bronconeumol</source><volume>39</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12749801</pub-id></citation></ref><ref id="b10-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellison-Loschmann</surname><given-names>L</given-names></name><name><surname>Sunyer</surname><given-names>J</given-names></name><name><surname>Plana</surname><given-names>E</given-names></name><etal/></person-group><year>2007</year><article-title>Socioeconomic status, asthma and chronic bronchitis in a large community-based study</article-title><source>Eur Respir J</source><volume>29</volume><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">17215316</pub-id></citation></ref><ref id="b11-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteban</surname><given-names>C</given-names></name><name><surname>Moraza</surname><given-names>J</given-names></name><name><surname>Quintana</surname><given-names>JM</given-names></name><etal/></person-group><year>2006</year><article-title>Use of medication and quality of life among patients with COPD</article-title><source>Respir Med</source><volume>100</volume><fpage>487</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">16039840</pub-id></citation></ref><ref id="b12-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Ichinose</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>COPD in Japan: the Nippon COPD epidemiology study</article-title><source>Respirology</source><volume>9</volume><fpage>458</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">15612956</pub-id></citation></ref><ref id="b13-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halbert</surname><given-names>RJ</given-names></name><name><surname>Natoli</surname><given-names>JL</given-names></name><name><surname>Gano</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Global burden of COPD: systematic review and meta-analysis</article-title><source>Eur Respir J</source><volume>28</volume><fpage>523</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16611654</pub-id></citation></ref><ref id="b14-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><year>2005</year><article-title>Respiratory complaints in Chinese. Cultural and diagnostic specificities</article-title><source>Chest</source><volume>127</volume><fpage>1942</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15947306</pub-id></citation></ref><ref id="b15-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegewald</surname><given-names>MJ</given-names></name><name><surname>Crapo</surname><given-names>RO</given-names></name></person-group><year>2007</year><article-title>Socioeconomic status and lung function</article-title><source>Chest</source><volume>132</volume><fpage>1608</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17998360</pub-id></citation></ref><ref id="b16-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herland</surname><given-names>K</given-names></name><name><surname>Akselen</surname><given-names>J-P</given-names></name><name><surname>Skjonsberg</surname><given-names>OH</given-names></name><etal/></person-group><year>2005</year><article-title>How representative are clinical study patients with asthma or COPD for a larger &#x0201c;real life&#x0201d; population of patients with obstructive lung disease?</article-title><source>Respir Med</source><volume>99</volume><fpage>11</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15672843</pub-id></citation></ref><ref id="b17-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackevicius</surname><given-names>C</given-names></name><name><surname>Joyce</surname><given-names>DP</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name><etal/></person-group><year>1997</year><article-title>Prehospitalization inhaled corticosteroid use in patients with COPD and asthma</article-title><source>Chest</source><volume>111</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">9041972</pub-id></citation></ref><ref id="b18-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><etal/></person-group><year>2005</year><article-title>Trends in the leading causes of death in the United States, 1970&#x02013;2002</article-title><source>JAMA</source><volume>294</volume><fpage>1255</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16160134</pub-id></citation></ref><ref id="b19-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Jung</surname><given-names>K-S</given-names></name><etal/></person-group><year>2005</year><article-title>Prevalence of chronic obstructive pulmonary disease in Korea. A population-based spirometry survey</article-title><source>Am J Respir Crit Care Med</source><volume>172</volume><fpage>842</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15976382</pub-id></citation></ref><ref id="b20-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname><given-names>AM</given-names></name><name><surname>Perez-Padilla</surname><given-names>R</given-names></name><name><surname>Jardim</surname><given-names>JR</given-names></name><etal/></person-group><year>2005</year><article-title>PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study</article-title><source>Lancet</source><volume>366</volume><fpage>1875</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16310554</pub-id></citation></ref><ref id="b21-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Legnani</surname><given-names>D</given-names></name><etal/></person-group><year>2007</year><article-title>Patient&#x02019;s perception of exacerbations of COPD &#x02013; the PERCEIVE study</article-title><source>Respir Med</source><volume>101</volume><fpage>453</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16938447</pub-id></citation></ref><ref id="b22-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>de la Roza</surname><given-names>C</given-names></name><name><surname>Morera</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>Chronic respiratory symptoms, spirometry and knowledge of COPD among general population</article-title><source>Respir Med</source><volume>100</volume><fpage>1973</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16626950</pub-id></citation></ref><ref id="b23-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>de la Roza</surname><given-names>C</given-names></name><name><surname>Naberan</surname><given-names>K</given-names></name><etal/></person-group><year>2007</year><article-title>Use of spirometry and patterns of prescribing in COPD in primary care</article-title><source>Respir Med</source><volume>101</volume><fpage>1753</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">17448651</pub-id></citation></ref><ref id="b24-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Pont</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers</article-title><source>Respir Med</source><volume>99</volume><fpage>985</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15950139</pub-id></citation></ref><ref id="b25-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Llor</surname><given-names>C</given-names></name><name><surname>Naberan</surname><given-names>K</given-names></name><etal/></person-group><year>2002</year><article-title>Use of the internet in a multicenter study on chronic obstructive pulmonary disease in primary care. Pilot phase of the EFEMAP study</article-title><source>Arch Bronconeumol</source><volume>38</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">12237014</pub-id></citation></ref><ref id="b26-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Mayordomo</surname><given-names>C</given-names></name><name><surname>Art&#x000e9;s</surname><given-names>M</given-names></name><etal/></person-group><collab>on Behalf of the EOLO Group</collab><year>1999</year><article-title>Treatment of chronic obstructive pulmonary disease and its exacerbations in General Practice</article-title><source>Respir Med</source><volume>93</volume><fpage>173</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10464874</pub-id></citation></ref><ref id="b27-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montn&#x000e9;mery</surname><given-names>OP</given-names></name><name><surname>Bengtsson</surname><given-names>P</given-names></name><name><surname>Elliot</surname><given-names>A</given-names></name><etal/></person-group><year>2001</year><article-title>Prevalence of obstructive lung diseases and respiratory symptoms in relation to living environment and socio-economic group</article-title><source>Respir Med</source><volume>95</volume><fpage>744</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11575896</pub-id></citation></ref><ref id="b28-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Calverley</surname><given-names>PMA</given-names></name><etal/></person-group><year>2001</year><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary</article-title><source>Am J Respir Crit Care Med</source><volume>163</volume><fpage>1256</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11316667</pub-id></citation></ref><ref id="b29-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Venegas</surname><given-names>A</given-names></name><name><surname>Sansores</surname><given-names>RH</given-names></name><name><surname>P&#x000e9;rez-Padilla</surname><given-names>R</given-names></name><etal/></person-group><year>2006</year><article-title>Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco</article-title><source>Am J Respir Crit Care Med</source><volume>173</volume><fpage>393</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16322646</pub-id></citation></ref><ref id="b30-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><etal/></person-group><year>2002</year><article-title>Impact of COPD in North America and Europe in 2000: subjects&#x02019; perspective of confronting COPD International Survey</article-title><source>Eur Respir J</source><volume>20</volume><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">12412667</pub-id></citation></ref><ref id="b31-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>N</given-names></name><name><surname>Lepage</surname><given-names>T</given-names></name><name><surname>Bourcereau</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><volume>18</volume><fpage>903</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11829094</pub-id></citation></ref><ref id="b32-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siva</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>RH</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><etal/></person-group><year>2007</year><article-title>Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial</article-title><source>Eur Respir J</source><volume>29</volume><fpage>906</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17301099</pub-id></citation></ref><ref id="b33-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobradillo</surname><given-names>V</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Gabriel</surname><given-names>R</given-names></name><etal/></person-group><year>2000</year><article-title>Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study</article-title><source>Chest</source><volume>118</volume><fpage>981</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11035667</pub-id></citation></ref><ref id="b34-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Andel</surname><given-names>AE</given-names></name><name><surname>Reisner</surname><given-names>C</given-names></name><name><surname>Menjoge</surname><given-names>SS</given-names></name><etal/></person-group><year>1999</year><article-title>Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995</article-title><source>Chest</source><volume>115</volume><fpage>703</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10084479</pub-id></citation></ref><ref id="b35-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viejo-Ba&#x000f1;uelos</surname><given-names>JL</given-names></name><name><surname>Pueyo-Bastida</surname><given-names>A</given-names></name><name><surname>Fueyo-Rodriguez</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>Characteristics of outpatients with COPD in daily practice: The E4 Spanish project</article-title><source>Respir Med</source><volume>100</volume><fpage>2137</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16831541</pub-id></citation></ref><ref id="b36-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y-C</given-names></name><name><surname>Lin</surname><given-names>J-M</given-names></name><name><surname>Li</surname><given-names>C-Y</given-names></name><etal/></person-group><year>2007</year><article-title>Prevalence and risks of chronic airway obstruction. A population cohort study in Taiwan</article-title><source>Chest</source><volume>131</volume><fpage>705</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">17356083</pub-id></citation></ref><ref id="b37-copd-3-803"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><etal/></person-group><year>2007</year><article-title>Prevalence of chronic obstructive pulmonary disease in China. A large, population-based survey</article-title><source>Am J Respir Crit Care Dis</source><volume>176</volume><fpage>753</fpage><lpage>60</lpage></citation></ref></ref-list></back><floats-wrap><fig id="f1-copd-3-803" position="float"><label>Figure 1</label><caption><p>Correlation between lung function (FEV<sub>1</sub>(%)) and the frequency of exacerbations the previous year (r = &#x02212;0.256; p &#x0003c; 0.0001).</p></caption><graphic xlink:href="copd-3-803f1"/></fig><table-wrap id="t1-copd-3-803" position="float"><label>Table 1</label><caption><p>Demographic and socioeconomic characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Global N = 833</th><th align="left" rowspan="1" colspan="1">Argentina N = 128</th><th align="left" rowspan="1" colspan="1">Ecuador N = 134</th><th align="left" rowspan="1" colspan="1">Spain N = 162</th><th align="left" rowspan="1" colspan="1">Hong Kong N = 153</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, men, %</td><td align="left" rowspan="1" colspan="1">79.3</td><td align="left" rowspan="1" colspan="1">71.1</td><td align="left" rowspan="1" colspan="1">70.9</td><td align="left" rowspan="1" colspan="1">90.7</td><td align="left" rowspan="1" colspan="1">90.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">69.5 (10.2)</td><td align="left" rowspan="1" colspan="1">66.8 (8.9)</td><td align="left" rowspan="1" colspan="1">71.7 (12.0)</td><td align="left" rowspan="1" colspan="1">69.0 (10.2)</td><td align="left" rowspan="1" colspan="1">74.9 (7.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">25.0 (5)</td><td align="left" rowspan="1" colspan="1">25.5 (4.3)</td><td align="left" rowspan="1" colspan="1">25.6 (5.2)</td><td align="left" rowspan="1" colspan="1">26.4 (4.8)</td><td align="left" rowspan="1" colspan="1">21.7 (3.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Active smokers, %</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">18.1</td><td align="left" rowspan="1" colspan="1">20.1</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">Pack-years</td><td align="left" rowspan="1" colspan="1">46.9 (33.1)</td><td align="left" rowspan="1" colspan="1">58.1 (31.1)</td><td align="left" rowspan="1" colspan="1">33.4 (31.7)</td><td align="left" rowspan="1" colspan="1">46.9 (29.9)</td><td align="left" rowspan="1" colspan="1">45.2 (33.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Biomass exposure, %</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">15.7</td><td align="left" rowspan="1" colspan="1">32.3</td><td align="left" rowspan="1" colspan="1">8.1</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity, %</td><td align="left" rowspan="1" colspan="1">42.5</td><td align="left" rowspan="1" colspan="1">38.1</td><td align="left" rowspan="1" colspan="1">41.4</td><td align="left" rowspan="1" colspan="1">63.4</td><td align="left" rowspan="1" colspan="1">42.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1">Socioeconomic, %</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;High</td><td align="left" rowspan="1" colspan="1">7.2</td><td align="left" rowspan="1" colspan="1">7.9</td><td align="left" rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Intermediate</td><td align="left" rowspan="1" colspan="1">53.2</td><td align="left" rowspan="1" colspan="1">62.2</td><td align="left" rowspan="1" colspan="1">50.8</td><td align="left" rowspan="1" colspan="1">67.1</td><td align="left" rowspan="1" colspan="1">21.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Low</td><td align="left" rowspan="1" colspan="1">39.6</td><td align="left" rowspan="1" colspan="1">29.9</td><td align="left" rowspan="1" colspan="1">36.7</td><td align="left" rowspan="1" colspan="1">26.6</td><td align="left" rowspan="1" colspan="1">77.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1">Residence, %</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rural</td><td align="left" rowspan="1" colspan="1">11.5</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">12.7</td><td align="left" rowspan="1" colspan="1">18.1</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Intermediate</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1">16.9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urban</td><td align="left" rowspan="1" colspan="1">81.6</td><td align="left" rowspan="1" colspan="1">91.3</td><td align="left" rowspan="1" colspan="1">76.1</td><td align="left" rowspan="1" colspan="1">65.0</td><td align="left" rowspan="1" colspan="1">94.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1">Education, %</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Up to primary</td><td align="left" rowspan="1" colspan="1">53.5</td><td align="left" rowspan="1" colspan="1">39.1</td><td align="left" rowspan="1" colspan="1">46.3</td><td align="left" rowspan="1" colspan="1">65.0</td><td align="left" rowspan="1" colspan="1">86.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Up to secondary</td><td align="left" rowspan="1" colspan="1">27.7</td><td align="left" rowspan="1" colspan="1">45.3</td><td align="left" rowspan="1" colspan="1">32.8</td><td align="left" rowspan="1" colspan="1">26.1</td><td align="left" rowspan="1" colspan="1">10.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Up to postgraduate</td><td align="left" rowspan="1" colspan="1">18.7</td><td align="left" rowspan="1" colspan="1">15.6</td><td align="left" rowspan="1" colspan="1">20.9</td><td align="left" rowspan="1" colspan="1">8.9</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-3-803"><p><bold>Abbreviations:</bold> BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-3-803" position="float"><label>Table 2</label><caption><p>Characteristics of COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Global N = 833</th><th align="left" rowspan="1" colspan="1">Argentina N = 128</th><th align="left" rowspan="1" colspan="1">Ecuador N = 134</th><th align="left" rowspan="1" colspan="1">Spain N = 162</th><th align="left" rowspan="1" colspan="1">Hong Kong N = 153</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Years of evolution</td><td align="left" rowspan="1" colspan="1">10.1</td><td align="left" rowspan="1" colspan="1">11.1</td><td align="left" rowspan="1" colspan="1">8.1</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">8.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Symptoms, %</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dyspnea Degree 0</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 1</td><td align="left" rowspan="1" colspan="1">11.5</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">16.8</td><td align="left" rowspan="1" colspan="1">10.3</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 2</td><td align="left" rowspan="1" colspan="1">31.4</td><td align="left" rowspan="1" colspan="1">36.2</td><td align="left" rowspan="1" colspan="1">32.8</td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 3</td><td align="left" rowspan="1" colspan="1">34.3</td><td align="left" rowspan="1" colspan="1">36.2</td><td align="left" rowspan="1" colspan="1">26.9</td><td align="left" rowspan="1" colspan="1">32.3</td><td align="left" rowspan="1" colspan="1">47.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 4</td><td align="left" rowspan="1" colspan="1">20.5</td><td align="left" rowspan="1" colspan="1">25.0</td><td align="left" rowspan="1" colspan="1">17.6</td><td align="left" rowspan="1" colspan="1">25.0</td><td align="left" rowspan="1" colspan="1">20.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chronic cough, %</td><td align="left" rowspan="1" colspan="1">69.6</td><td align="left" rowspan="1" colspan="1">71.2</td><td align="left" rowspan="1" colspan="1">87.4</td><td align="left" rowspan="1" colspan="1">76.6</td><td align="left" rowspan="1" colspan="1">52.3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sputum, %</td><td align="left" rowspan="1" colspan="1">70.5</td><td align="left" rowspan="1" colspan="1">75.4</td><td align="left" rowspan="1" colspan="1">92.1</td><td align="left" rowspan="1" colspan="1">59.4</td><td align="left" rowspan="1" colspan="1">63.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Lung function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FVC, ml</td><td align="left" rowspan="1" colspan="1">2312.2 (920.5)</td><td align="left" rowspan="1" colspan="1">2472.5 (804.9)</td><td align="left" rowspan="1" colspan="1">2295.1 (750.2)</td><td align="left" rowspan="1" colspan="1">2709.9 (1016.9)</td><td align="left" rowspan="1" colspan="1">1448.9 (602.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FVC,% predicted</td><td align="left" rowspan="1" colspan="1">59.7 (19.4)</td><td align="left" rowspan="1" colspan="1">62.2 (16.0)</td><td align="left" rowspan="1" colspan="1">65.4 (17.7)</td><td align="left" rowspan="1" colspan="1">66.8 (19.5)</td><td align="left" rowspan="1" colspan="1">40.3 (14.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, mL</td><td align="left" rowspan="1" colspan="1">1143.8 (518.7)</td><td align="left" rowspan="1" colspan="1">1147.2 (465.4)</td><td align="left" rowspan="1" colspan="1">1406.0 (627.1)</td><td align="left" rowspan="1" colspan="1">1279.5 (547.0)</td><td align="left" rowspan="1" colspan="1">841,6 (391.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, % predicted</td><td align="left" rowspan="1" colspan="1">42.7 (17.8)</td><td align="left" rowspan="1" colspan="1">41.1 (15.4)</td><td align="left" rowspan="1" colspan="1">58.8 (23.5)</td><td align="left" rowspan="1" colspan="1">44.3 (17.3)</td><td align="left" rowspan="1" colspan="1">34.3 (13.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC</td><td align="left" rowspan="1" colspan="1">50.6 (14.5)</td><td align="left" rowspan="1" colspan="1">47.0 (13.7)</td><td align="left" rowspan="1" colspan="1">60.9 (15.9)</td><td align="left" rowspan="1" colspan="1">48.0 (13.1)</td><td align="left" rowspan="1" colspan="1">59.0 (14.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>During the last year</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Number of exacerbations</td><td align="left" rowspan="1" colspan="1">1.6 (2.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.9)</td><td align="left" rowspan="1" colspan="1">0.9 (1.4)</td><td align="left" rowspan="1" colspan="1">1.8 (1.9)</td><td align="left" rowspan="1" colspan="1">1.9 (3.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Emergency visits</td><td align="left" rowspan="1" colspan="1">0.9 (1.5)</td><td align="left" rowspan="1" colspan="1">1.3 (1.8)</td><td align="left" rowspan="1" colspan="1">0.3 (0.7)</td><td align="left" rowspan="1" colspan="1">0.9 (1.5)</td><td align="left" rowspan="1" colspan="1">1.3 (2.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Admissions</td><td align="left" rowspan="1" colspan="1">0.6 (1.0)</td><td align="left" rowspan="1" colspan="1">0.5 (1.1)</td><td align="left" rowspan="1" colspan="1">0.4 (0.8)</td><td align="left" rowspan="1" colspan="1">0.6 (1.0)</td><td align="left" rowspan="1" colspan="1">1.0 (1.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IC admissions</td><td align="left" rowspan="1" colspan="1">0.1 (0.3)</td><td align="left" rowspan="1" colspan="1">0.2 (0.5)</td><td align="left" rowspan="1" colspan="1">0.0 (0.3)</td><td align="left" rowspan="1" colspan="1">0.1 (0.4)</td><td align="left" rowspan="1" colspan="1">0.0 (0.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Visits to GP</td><td align="left" rowspan="1" colspan="1">1.5 (2.5)</td><td align="left" rowspan="1" colspan="1">2.6 (3.7)</td><td align="left" rowspan="1" colspan="1">1.6 (3.2)</td><td align="left" rowspan="1" colspan="1">2.0 (3.2)</td><td align="left" rowspan="1" colspan="1">1.2 (2.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Visits to chest specialist</td><td align="left" rowspan="1" colspan="1">2.4 (2.6)</td><td align="left" rowspan="1" colspan="1">4.6 (3.8)</td><td align="left" rowspan="1" colspan="1">2.8 (2.7)</td><td align="left" rowspan="1" colspan="1">1.8 (1.8)</td><td align="left" rowspan="1" colspan="1">1.8 (2.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-copd-3-803"><p><bold>Abbreviations:</bold> FVC, forced vital capacity; FEV<sub>1</sub>, forced expiratory volume in the first second; IC, intensive care; GP, general practitioner.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-copd-3-803" position="float"><label>Table 3</label><caption><p>Treatment administered for stable COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Global N = 833</th><th align="left" rowspan="1" colspan="1">Argentina N = 128</th><th align="left" rowspan="1" colspan="1">Ecuador N = 134</th><th align="left" rowspan="1" colspan="1">Spain N = 162</th><th align="left" rowspan="1" colspan="1">Hong Kong N = 153</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">Inhaled treatment, %</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SABA</td><td align="left" rowspan="1" colspan="1">74.8</td><td align="left" rowspan="1" colspan="1">85.6</td><td align="left" rowspan="1" colspan="1">69.5</td><td align="left" rowspan="1" colspan="1">75.3</td><td align="left" rowspan="1" colspan="1">97.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ipratropium</td><td align="left" rowspan="1" colspan="1">48.3</td><td align="left" rowspan="1" colspan="1">52.5</td><td align="left" rowspan="1" colspan="1">30.4</td><td align="left" rowspan="1" colspan="1">21.1</td><td align="left" rowspan="1" colspan="1">90.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tiotropium</td><td align="left" rowspan="1" colspan="1">35.5</td><td align="left" rowspan="1" colspan="1">33.9</td><td align="left" rowspan="1" colspan="1">40.6</td><td align="left" rowspan="1" colspan="1">73.9</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LABA</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">13.3</td><td align="left" rowspan="1" colspan="1">9.1</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ICS</td><td align="left" rowspan="1" colspan="1">21.8</td><td align="left" rowspan="1" colspan="1">12.7</td><td align="left" rowspan="1" colspan="1">31.2</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="1" colspan="1">44.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LABA/ICS</td><td align="left" rowspan="1" colspan="1">45.9</td><td align="left" rowspan="1" colspan="1">72.8</td><td align="left" rowspan="1" colspan="1">35.9</td><td align="left" rowspan="1" colspan="1">68.3</td><td align="left" rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1">Oral treatment, %</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Teophyllines</td><td align="left" rowspan="1" colspan="1">25.3</td><td align="left" rowspan="1" colspan="1">18.6</td><td align="left" rowspan="1" colspan="1">26.6</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">46.6</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mucolytics</td><td align="left" rowspan="1" colspan="1">10.1</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">13.2</td><td align="left" rowspan="1" colspan="1">20.4</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Oral corticosteroids</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">11.7</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1">Other, %</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LTOT</td><td align="left" rowspan="1" colspan="1">21.1</td><td align="left" rowspan="1" colspan="1">14.4</td><td align="left" rowspan="1" colspan="1">17.9</td><td align="left" rowspan="1" colspan="1">24.6</td><td align="left" rowspan="1" colspan="1">17.7</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rehabilitation</td><td align="left" rowspan="1" colspan="1">15.6</td><td align="left" rowspan="1" colspan="1">30.5</td><td align="left" rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">4.9</td><td align="left" rowspan="1" colspan="1">7.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antiinfluenza vaccine</td><td align="left" rowspan="1" colspan="1">58.6</td><td align="left" rowspan="1" colspan="1">72.0</td><td align="left" rowspan="1" colspan="1">22.6</td><td align="left" rowspan="1" colspan="1">80.3</td><td align="left" rowspan="1" colspan="1">48.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antipneumococcal vaccine</td><td align="left" rowspan="1" colspan="1">32.5</td><td align="left" rowspan="1" colspan="1">64.4</td><td align="left" rowspan="1" colspan="1">18.7</td><td align="left" rowspan="1" colspan="1">43.6</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-copd-3-803"><p><bold>Abbreviations:</bold> SABA, short-acting beta2 agonist; LABA, long-acting beta2-agonist; ICS, inhaled corticosteroid; LTOT, long-term oxygen therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-copd-3-803" position="float"><label>Table 4</label><caption><p>Inadequate treatment for stable COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Global N = 833</th><th align="left" rowspan="1" colspan="1">Argentina N = 128</th><th align="left" rowspan="1" colspan="1">Ecuador N = 134</th><th align="left" rowspan="1" colspan="1">Spain N = 162</th><th align="left" rowspan="1" colspan="1">Hong Kong N = 153</th><th align="left" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">Inhaled corticosteroids</td></tr><tr><td colspan="7" align="left" rowspan="1">Indicated (n = 306)</td></tr><tr><td colspan="7" align="left" rowspan="1">Prescribed (n = 527)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indicated, not prescribed</td><td align="left" rowspan="1" colspan="1">27.8</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="left" rowspan="1" colspan="1">18.7</td><td align="left" rowspan="1" colspan="1">17.4</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Prescribed, not indicated</td><td align="left" rowspan="1" colspan="1">41.9</td><td align="left" rowspan="1" colspan="1">38.6</td><td align="left" rowspan="1" colspan="1">65.1</td><td align="left" rowspan="1" colspan="1">33.3</td><td align="left" rowspan="1" colspan="1">33.3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="7" align="left" rowspan="1">Theophyllines</td></tr><tr><td colspan="7" align="left" rowspan="1">Indicated (n = 123)</td></tr><tr><td colspan="7" align="left" rowspan="1">Prescribed (n = 222)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indicated, not prescribed</td><td align="left" rowspan="1" colspan="1">79.6</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">72.2</td><td align="left" rowspan="1" colspan="1">92.9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Prescribed, not indicated</td><td align="left" rowspan="1" colspan="1">26.6</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">26.4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">33.8</td><td align="left" rowspan="1" colspan="1">0.0016</td></tr></tbody></table></table-wrap><table-wrap id="t5-copd-3-803" position="float"><label>Table 5</label><caption><p>Demographic and clinical characteristics of patients according to estimated social class</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">Low N = 324</th><th align="left" rowspan="1" colspan="1">Intermediate N = 436</th><th align="left" rowspan="1" colspan="1">High N = 59</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, men</td><td align="left" rowspan="1" colspan="1">76.5</td><td align="left" rowspan="1" colspan="1">81.9</td><td align="left" rowspan="1" colspan="1">72.8</td><td align="left" rowspan="1" colspan="1">0.091</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">71.3 (9.6)</td><td align="left" rowspan="1" colspan="1">68.8 (10.2)</td><td align="left" rowspan="1" colspan="1">63.4 (10.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Active smoker</td><td align="left" rowspan="1" colspan="1">16.9</td><td align="left" rowspan="1" colspan="1">20.2</td><td align="left" rowspan="1" colspan="1">24.1</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Pack-years</td><td align="left" rowspan="1" colspan="1">45.6 (33.2)</td><td align="left" rowspan="1" colspan="1">46.7 (31.6)</td><td align="left" rowspan="1" colspan="1">53.3 (39.6)</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Biomass exposure</td><td align="left" rowspan="1" colspan="1">36.1</td><td align="left" rowspan="1" colspan="1">13.5</td><td align="left" rowspan="1" colspan="1">18.6</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Years of evolution</td><td align="left" rowspan="1" colspan="1">9.3 (8.5)</td><td align="left" rowspan="1" colspan="1">10.7 (10.3)</td><td align="left" rowspan="1" colspan="1">10 (9.1)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity</td><td align="left" rowspan="1" colspan="1">40.2</td><td align="left" rowspan="1" colspan="1">44.8</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline dyspnea</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 0</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 1</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">13.7</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 2</td><td align="left" rowspan="1" colspan="1">30.5</td><td align="left" rowspan="1" colspan="1">32.1</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 3</td><td align="left" rowspan="1" colspan="1">37.5</td><td align="left" rowspan="1" colspan="1">32.6</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Degree 4</td><td align="left" rowspan="1" colspan="1">23.1</td><td align="left" rowspan="1" colspan="1">19.4</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">Lung function</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FVC, mL</td><td align="left" rowspan="1" colspan="1">2012.5 (829.2)</td><td align="left" rowspan="1" colspan="1">2442.4 (885.3)</td><td align="left" rowspan="1" colspan="1">3033.5 (1116.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FVC, %</td><td align="left" rowspan="1" colspan="1">55.5 (19.5)</td><td align="left" rowspan="1" colspan="1">61.5 (18.4)</td><td align="left" rowspan="1" colspan="1">69.2 (19.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, mL</td><td align="left" rowspan="1" colspan="1">1053.2 (485.8)</td><td align="left" rowspan="1" colspan="1">1164.4 (515.5)</td><td align="left" rowspan="1" colspan="1">1487.8 (587.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, %</td><td align="left" rowspan="1" colspan="1">42.1 (18.4)</td><td align="left" rowspan="1" colspan="1">42.1 (17.0)</td><td align="left" rowspan="1" colspan="1">47.4 (18.1)</td><td align="left" rowspan="1" colspan="1">0.1311<xref ref-type="table-fn" rid="tfn4-copd-3-803">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC, %</td><td align="left" rowspan="1" colspan="1">53.8 (15.2)</td><td align="left" rowspan="1" colspan="1">48.2 (13.7)</td><td align="left" rowspan="1" colspan="1">50.5 (13.3)</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr><tr><td colspan="5" align="left" rowspan="1">Previous 12 months</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Medical visits GP</td><td align="left" rowspan="1" colspan="1">1.5 (2.4)</td><td align="left" rowspan="1" colspan="1">1.6 (2.8)</td><td align="left" rowspan="1" colspan="1">1.1 (1.5)</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Medical visits specialist</td><td align="left" rowspan="1" colspan="1">2.4 (2.2)</td><td align="left" rowspan="1" colspan="1">2.5 (2.9)</td><td align="left" rowspan="1" colspan="1">2.2 (2.6)</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Exacerbations</td><td align="left" rowspan="1" colspan="1">1.7 (2.4)</td><td align="left" rowspan="1" colspan="1">1.5 (1.7)</td><td align="left" rowspan="1" colspan="1">1.4 (1.5)</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Emergency visits</td><td align="left" rowspan="1" colspan="1">1.1 (1.8)</td><td align="left" rowspan="1" colspan="1">0.8 (1.3)</td><td align="left" rowspan="1" colspan="1">0.6 (1.3)</td><td align="left" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Admissions</td><td align="left" rowspan="1" colspan="1">0.7 (1.2)</td><td align="left" rowspan="1" colspan="1">0.5 (0.8)</td><td align="left" rowspan="1" colspan="1">0.5 (0.8)</td><td align="left" rowspan="1" colspan="1">0.083</td></tr><tr><td colspan="5" align="left" rowspan="1">Treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SABA</td><td align="left" rowspan="1" colspan="1">83.6</td><td align="left" rowspan="1" colspan="1">71.1</td><td align="left" rowspan="1" colspan="1">53.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ipratropium</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">39.4</td><td align="left" rowspan="1" colspan="1">24.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tiotropium</td><td align="left" rowspan="1" colspan="1">22.5</td><td align="left" rowspan="1" colspan="1">42.4</td><td align="left" rowspan="1" colspan="1">57.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LABA</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">7.6</td><td align="left" rowspan="1" colspan="1">29.6</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ICS</td><td align="left" rowspan="1" colspan="1">34.3</td><td align="left" rowspan="1" colspan="1">13.7</td><td align="left" rowspan="1" colspan="1">9.2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LABA/ICS</td><td align="left" rowspan="1" colspan="1">34.3</td><td align="left" rowspan="1" colspan="1">54.6</td><td align="left" rowspan="1" colspan="1">44.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Theophyllines</td><td align="left" rowspan="1" colspan="1">35.6</td><td align="left" rowspan="1" colspan="1">23.7</td><td align="left" rowspan="1" colspan="1">22.2</td><td align="left" rowspan="1" colspan="1">0.0014</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mucolytics</td><td align="left" rowspan="1" colspan="1">6.5</td><td align="left" rowspan="1" colspan="1">14.4</td><td align="left" rowspan="1" colspan="1">9.2</td><td align="left" rowspan="1" colspan="1">0.0033</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rehabilitation</td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1">15.7</td><td align="left" rowspan="1" colspan="1">31.5</td><td align="left" rowspan="1" colspan="1">0.0036</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LTOT</td><td align="left" rowspan="1" colspan="1">21.9</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1">22.2</td><td align="left" rowspan="1" colspan="1">0.8988</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antiinfluenza vaccination</td><td align="left" rowspan="1" colspan="1">56.2</td><td align="left" rowspan="1" colspan="1">62.2</td><td align="left" rowspan="1" colspan="1">48.1</td><td align="left" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antipneumococcal vaccination</td><td align="left" rowspan="1" colspan="1">23.8</td><td align="left" rowspan="1" colspan="1">38.9</td><td align="left" rowspan="1" colspan="1">35.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-copd-3-803"><label>*</label><p>p = 0.0447 between high and low social class.</p></fn><fn id="tfn5-copd-3-803"><p><bold>Abbreviations:</bold> FVC, forced vital capacity; FEV<sub>1</sub>, forced espiratory volume in the first second; GP, general practitioner; SABA, short-acting beta2-agonist; LABA, long-acting beta2-agonist; ICS, inhaled corticosteroid; LTOT, long-term oxygen therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-copd-3-803" position="float"><label>Table 6</label><caption><p>Multivariate stepwise regression models of dependent variables significantly and independently associated with the following independent variables: frequency of exacerbations (0&#x02013;1 versus &#x0003e;1), treatment with ICS, combination therapy LABA + ICS and tiotropium (all presented as yes versus no)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="left" rowspan="1">a) Frequency of exacerbations<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Point estimate</th><th align="left" rowspan="1" colspan="1">95% confidence limits</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age &#x0003e;75 vs 65&#x02013;75 yrs</td><td align="left" rowspan="1" colspan="1">0.948</td><td align="left" rowspan="1" colspan="1">0.596&#x02013;1.508</td><td align="left" rowspan="1" colspan="1">0.8223</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x0003e;75 vs &#x0003c;65 yrs</td><td align="left" rowspan="1" colspan="1">2.088</td><td align="left" rowspan="1" colspan="1">1.280&#x02013;3.406</td><td align="left" rowspan="1" colspan="1">0.0032</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea II vs 0&#x02013;I</td><td align="left" rowspan="1" colspan="1">4.399</td><td align="left" rowspan="1" colspan="1">1.618&#x02013;11.962</td><td align="left" rowspan="1" colspan="1">0.0037</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea III vs 0&#x02013;I</td><td align="left" rowspan="1" colspan="1">6.223</td><td align="left" rowspan="1" colspan="1">2.308&#x02013;16.782</td><td align="left" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea IV vs 0&#x02013;I</td><td align="left" rowspan="1" colspan="1">14.249</td><td align="left" rowspan="1" colspan="1">5.110&#x02013;39.735</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhaled corticosteroids</td><td align="left" rowspan="1" colspan="1">2.535</td><td align="left" rowspan="1" colspan="1">1.611&#x02013;3.991</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody><tbody><tr><td colspan="4" align="left" rowspan="1">b) Treatment with inhaled corticosteroids<hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Variable</bold></td><td align="left" rowspan="1" colspan="1"><bold>Point estimate</bold></td><td align="left" rowspan="1" colspan="1"><bold>95% confidence limits</bold></td><td align="left" rowspan="1" colspan="1"><bold>p value</bold></td></tr><tr><td colspan="4" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">FEV1 &#x0003c;50% vs &#x0003e;50%</td><td align="left" rowspan="1" colspan="1">1.994</td><td align="left" rowspan="1" colspan="1">1.059&#x02013;3.754</td><td align="left" rowspan="1" colspan="1">0.0326</td></tr><tr><td align="left" rowspan="1" colspan="1">Expectoration</td><td align="left" rowspan="1" colspan="1">2.595</td><td align="left" rowspan="1" colspan="1">1.457&#x02013;4.619</td><td align="left" rowspan="1" colspan="1">0.0012</td></tr><tr><td align="left" rowspan="1" colspan="1">Low class vs high class</td><td align="left" rowspan="1" colspan="1">5.875</td><td align="left" rowspan="1" colspan="1">1.907&#x02013;18.098</td><td align="left" rowspan="1" colspan="1">0.0020</td></tr><tr><td align="left" rowspan="1" colspan="1">Middle class vs high class</td><td align="left" rowspan="1" colspan="1">4.667</td><td align="left" rowspan="1" colspan="1">1.620&#x02013;13.448</td><td align="left" rowspan="1" colspan="1">0.0043</td></tr><tr><td align="left" rowspan="1" colspan="1">Former vs active smoker</td><td align="left" rowspan="1" colspan="1">4.663</td><td align="left" rowspan="1" colspan="1">2.386&#x02013;9.113</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Argentina vs Spain</td><td align="left" rowspan="1" colspan="1">1.599</td><td align="left" rowspan="1" colspan="1">0.762&#x02013;3.358</td><td align="left" rowspan="1" colspan="1">0.2148</td></tr><tr><td align="left" rowspan="1" colspan="1">Ecuador vs Spain</td><td align="left" rowspan="1" colspan="1">1.484</td><td align="left" rowspan="1" colspan="1">0.447&#x02013;4.923</td><td align="left" rowspan="1" colspan="1">0.5193</td></tr><tr><td align="left" rowspan="1" colspan="1">Hong Kong vs Spain</td><td align="left" rowspan="1" colspan="1">0.185</td><td align="left" rowspan="1" colspan="1">0.088&#x02013;0.388</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody><tbody><tr><td colspan="4" align="left" rowspan="1">c) Treatment with combination LABA + ICSs<hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Variable</bold></td><td align="left" rowspan="1" colspan="1"><bold>Point estimate</bold></td><td align="left" rowspan="1" colspan="1"><bold>95% confidence limits</bold></td><td align="left" rowspan="1" colspan="1"><bold>P value</bold></td></tr><tr><td colspan="4" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Education secondary vs primary</td><td align="left" rowspan="1" colspan="1">1.689</td><td align="left" rowspan="1" colspan="1">1.031&#x02013;2.766</td><td align="left" rowspan="1" colspan="1">0.0373</td></tr><tr><td align="left" rowspan="1" colspan="1">Education postgraduate vs primary</td><td align="left" rowspan="1" colspan="1">0.925</td><td align="left" rowspan="1" colspan="1">0.482&#x02013;1.778</td><td align="left" rowspan="1" colspan="1">0.8160</td></tr><tr><td align="left" rowspan="1" colspan="1">Cough</td><td align="left" rowspan="1" colspan="1">1.756</td><td align="left" rowspan="1" colspan="1">1.073&#x02013;2.875</td><td align="left" rowspan="1" colspan="1">0.0252</td></tr><tr><td align="left" rowspan="1" colspan="1">Former vs active smoker</td><td align="left" rowspan="1" colspan="1">3.139</td><td align="left" rowspan="1" colspan="1">1.754&#x02013;5.617</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Argentina vs Spain</td><td align="left" rowspan="1" colspan="1">1.110</td><td align="left" rowspan="1" colspan="1">0.628&#x02013;1.962</td><td align="left" rowspan="1" colspan="1">0.7203</td></tr><tr><td align="left" rowspan="1" colspan="1">Ecuador vs Spain</td><td align="left" rowspan="1" colspan="1">0.181</td><td align="left" rowspan="1" colspan="1">0.101&#x02013;0.326</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hong Kong vs Spain</td><td align="left" rowspan="1" colspan="1">0.073</td><td align="left" rowspan="1" colspan="1">0.039&#x02013;0.137</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody><tbody><tr><td colspan="4" align="left" rowspan="1">d) Treatment with tiotropium<hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Variable</bold></td><td align="left" rowspan="1" colspan="1"><bold>Point estimate</bold></td><td align="left" rowspan="1" colspan="1"><bold>95% confidence limits</bold></td><td align="left" rowspan="1" colspan="1"><bold>P value</bold></td></tr><tr><td colspan="4" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Former vs active smoker</td><td align="left" rowspan="1" colspan="1">1.442</td><td align="left" rowspan="1" colspan="1">0.803&#x02013;2.590</td><td align="left" rowspan="1" colspan="1">0.2198</td></tr><tr><td align="left" rowspan="1" colspan="1">Argentina vs Spain</td><td align="left" rowspan="1" colspan="1">0.166</td><td align="left" rowspan="1" colspan="1">0.096&#x02013;0.286</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Ecuador vs Spain</td><td align="left" rowspan="1" colspan="1">0.234</td><td align="left" rowspan="1" colspan="1">0.135&#x02013;0.403</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hong Kong vs Spain</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">0.002&#x02013;0.22</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></table-wrap></floats-wrap></article>